Publication:
Adverse Effect of Phenytoin on Glucocorticoid Replacement in a Child With Adrenal Insufficiency

dc.authorscopusid59818933100
dc.authorscopusid56809300400
dc.authorscopusid55412732700
dc.authorscopusid7102765260
dc.contributor.authorKara, C.
dc.contributor.authorUcakturk, A.
dc.contributor.authorAydin, T.F.
dc.contributor.authorAydin, Mahmut
dc.date.accessioned2020-06-21T14:47:15Z
dc.date.available2020-06-21T14:47:15Z
dc.date.issued2010
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Kara] Cengiz, Department of Pediatric Endocrinology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Ucakturk] Seyit Ahmet, Department of Pediatric Endocrinology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Aydin] Ömer Faruk, Department of Neurology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Aydin] Murat, Department of Pediatric Endocrinology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractChronic administration of antiepileptic agents such as phenytoin can increase clearance rates of cortisol and synthetic glucocorticoids through hepatic microsomal enzyme induction. However, data concerning an adverse interaction between antiepileptic and steroid drugs are scarce. We herein report an adolescent boy with primary adrenal insufficiency that developed glucocorticoid deficiency after added phenytoin treatment. The patient had an increased requirement for hydrocortisone replacement, and two episodes of vomiting, hyponatremia and mild hypoglycemia. His ACTH levels were markedly elevated. Fifteen days after stopping phenytoin, his serum ACTH concentration returned to normal range. Even though the hydrocortisone dose was gradually decreased, hyponatremia and vomiting have not recurred. In conclusion, we suggest that drugs such as phenytoin affecting hepatic clearance of synthetic glucocorticoids and mineralocorticoids should not be preferred for therapy in patients with adrenal insufficiency. If their use is vital, one should be aware of increased replacement requirements for steroid drugs, and patients should be closely monitored. © Freund Publishing House Ltd.en_US
dc.identifier.doi10.1515/jpem.2010.154
dc.identifier.endpage966en_US
dc.identifier.issn2191-0251
dc.identifier.issue9en_US
dc.identifier.pmid21175098
dc.identifier.scopus2-s2.0-77958600461
dc.identifier.scopusqualityQ4
dc.identifier.startpage963en_US
dc.identifier.urihttps://doi.org/10.1515/jpem.2010.154
dc.identifier.volume23en_US
dc.identifier.wosWOS:000282928800018
dc.identifier.wosqualityQ3
dc.language.isoenen_US
dc.publisherWalter de Gruyter GmbHen_US
dc.relation.ispartofJournal of Pediatric Endocrinology & Metabolismen_US
dc.relation.journalJournal of Pediatric Endocrinology & Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdrenal Insufficiencyen_US
dc.subjectChildrenen_US
dc.subjectGlucocorticoid Replacementen_US
dc.subjectPhenytoinen_US
dc.titleAdverse Effect of Phenytoin on Glucocorticoid Replacement in a Child With Adrenal Insufficiencyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files